BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Career Advice

  Successfully Compete for Jobs in a Crowded Remote Work Talent Pool

  With more and more people applying for remote positions, how can you stand out among the massive stacks of applications?

  January 20, 2022

   · 

  3 min read

   · 

  Hannah Harshman
• 

  Business

  Cancer Biotech Boosts Funding and Names New CEO

  The funds will be used to advance the firm’s precision oncology research efforts and pipeline, particularly those involving the creation of alteration-specific therapies.

  January 20, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Psychedelic Biotech Takes SPAC Track to Nasdaq

  Psychedelic-focused drug company Eleusis is merging with Silver Spike Acquisition Corp. II, a special purposes acquisition company, and heading to the Nasdaq with a combined enterprise value of $446 million.

  January 20, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  The Pipeline Gets the Cash as Zymeworks Trims 25% of Staff

  As part of a company-wide workforce reduction, it will cut its employee headcount by at least 25% by the end of the year, and 50% of its senior management team are leaving the company.

  January 20, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  BioSpace Movers & Shakers, Jan. 21

  Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth.

  January 20, 2022

   · 

  8 min read

   · 

  Alex Keown
• 

  Business

  Merck’s Clyburn Departs for Different Healthcare Realm

  Merck announced that Frank Clyburn, executive vice president and president of human health, will be leaving the company on February 1, 2022.

  January 20, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Foresite Labs Hatches Big-Data-Driven Companies Destined to Shake up Healthcare

  Such a deep, data-driven approach is enabling precision medicine, in particular, which is expanding from oncology to autoimmune diseases and other conditions.

  January 20, 2022

   · 

  5 min read

   · 

  Gail Dutton
• 

  Drug Development

  ImmPACT Bio Gains $111M, a New Leader and Positive Trial Results

  ImmPACT Bio provided an optimistic update on a Phase I clinical study evaluating its CD19-CD20 bi-specific Chimeric Antigen Receptor T-cell (CAR-T) therapy.

  January 20, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  BioMidwest

  Research Roundup: Nanotherapy and Islet Transplants for Diabetes and More

  For about a century, the way to treat Type 1 diabetes has been via insulin injections. Although research has been conducted on pancreatic islet transplants, it’s a tough nut to crack in terms of organ rejection. There’s been a potential breakthrough in that area involving nanotherapy.

  January 20, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  COVID-19 Brief: Vaccinations for 5 and Under Coming as Omicron Proves More Dangerous

  Dr. Anthony Fauci expects the FDA will authorize the Pfizer-BioNTech vaccine for children under the age of five in the next month.

  January 20, 2022

   · 

  6 min read

   · 

  Mark Terry